GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 8.04 Billion KRW | 25.66% |
| 2022 | 6.4 Billion KRW | 263.82% |
| 2021 | -3.9 Billion KRW | 91.25% |
| 2020 | -44.66 Billion KRW | -1734.51% |
| 2019 | -2.43 Billion KRW | -160.73% |
| 2018 | 4 Billion KRW | 137.95% |
| 2017 | -10.56 Billion KRW | -910.14% |
| 2016 | 1.3 Billion KRW | 115.29% |
| 2015 | -8.52 Billion KRW | -32.44% |
| 2014 | -6.44 Billion KRW | -104.73% |
| 2013 | -3.14 Billion KRW | -141.53% |
| 2012 | 7.57 Billion KRW | 24726.53% |
| 2011 | 30.51 Million KRW | 103.31% |
| 2010 | -922.83 Million KRW | -114.79% |
| 2009 | 6.23 Billion KRW | 699.01% |
| 2008 | 780.79 Million KRW | 105.28% |
| 2007 | -14.79 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 10.64 Billion KRW | 32.3% |
| 2024 Q2 | 19.43 Billion KRW | 56.51% |
| 2023 Q1 | 4.33 Billion KRW | -32.38% |
| 2023 Q2 | 5.52 Billion KRW | 27.51% |
| 2023 FY | 8.04 Billion KRW | 25.66% |
| 2023 Q3 | 2.42 Billion KRW | -56.16% |
| 2023 Q4 | 8.04 Billion KRW | 232.45% |
| 2022 Q1 | -10.58 Billion KRW | -170.83% |
| 2022 Q3 | 1.4 Billion KRW | 127.31% |
| 2022 Q4 | 6.4 Billion KRW | 354.93% |
| 2022 FY | 6.4 Billion KRW | 263.82% |
| 2022 Q2 | -5.15 Billion KRW | 51.31% |
| 2021 FY | -3.9 Billion KRW | 91.25% |
| 2021 Q1 | -31.8 Billion KRW | 28.79% |
| 2021 Q2 | -13.6 Billion KRW | 57.23% |
| 2021 Q3 | -9.64 Billion KRW | 29.07% |
| 2021 Q4 | -3.9 Billion KRW | 59.48% |
| 2020 FY | -44.66 Billion KRW | -1734.51% |
| 2020 Q2 | -9.11 Billion KRW | -22.73% |
| 2020 Q3 | -24.86 Billion KRW | -172.62% |
| 2020 Q4 | -44.66 Billion KRW | -79.66% |
| 2020 Q1 | -7.43 Billion KRW | -205.18% |
| 2019 Q1 | -1.35 Billion KRW | -133.92% |
| 2019 FY | -2.43 Billion KRW | -160.73% |
| 2019 Q3 | -5.13 Billion KRW | -155.57% |
| 2019 Q2 | -2 Billion KRW | -47.66% |
| 2019 Q4 | -2.43 Billion KRW | 52.55% |
| 2018 Q3 | 663.85 Million KRW | -77.88% |
| 2018 Q4 | 4 Billion KRW | 503.92% |
| 2018 Q2 | 3 Billion KRW | 130.28% |
| 2018 Q1 | -9.91 Billion KRW | 6.2% |
| 2018 FY | 4 Billion KRW | 137.95% |
| 2017 FY | -10.56 Billion KRW | -910.14% |
| 2017 Q4 | -10.56 Billion KRW | -211.73% |
| 2017 Q3 | 9.45 Billion KRW | 22.09% |
| 2017 Q2 | 7.74 Billion KRW | 224.17% |
| 2017 Q1 | 2.38 Billion KRW | 83.21% |
| 2016 Q2 | -6.39 Billion KRW | 37.2% |
| 2016 FY | 1.3 Billion KRW | 115.29% |
| 2016 Q4 | 1.3 Billion KRW | 159.2% |
| 2016 Q3 | -2.2 Billion KRW | 65.55% |
| 2016 Q1 | -10.18 Billion KRW | -19.36% |
| 2015 FY | -8.52 Billion KRW | -32.44% |
| 2015 Q4 | -8.52 Billion KRW | -1.78% |
| 2015 Q3 | -8.38 Billion KRW | -0.52% |
| 2015 Q2 | -8.33 Billion KRW | -18.0% |
| 2015 Q1 | -7.06 Billion KRW | -9.7% |
| 2014 Q3 | -2.41 Billion KRW | -256.54% |
| 2014 Q2 | -677.86 Million KRW | 59.26% |
| 2014 Q1 | -1.66 Billion KRW | 47.11% |
| 2014 FY | -6.44 Billion KRW | -104.73% |
| 2014 Q4 | -6.44 Billion KRW | -166.48% |
| 2013 FY | -3.14 Billion KRW | -141.53% |
| 2013 Q4 | -3.14 Billion KRW | -816.61% |
| 2013 Q3 | -343.19 Million KRW | -319.77% |
| 2013 Q2 | -81.75 Million KRW | 96.58% |
| 2013 Q1 | -2.39 Billion KRW | -131.56% |
| 2012 Q4 | 7.57 Billion KRW | 0.0% |
| 2012 FY | 7.57 Billion KRW | 24726.53% |
| 2012 Q1 | 7.08 Billion KRW | 0.0% |
| 2011 FY | 30.51 Million KRW | 103.31% |
| 2011 Q3 | 636.77 Million KRW | 8.37% |
| 2011 Q2 | 587.59 Million KRW | 402.78% |
| 2011 Q1 | -194.06 Million KRW | 0.0% |
| 2010 Q1 | 8.09 Billion KRW | 0.0% |
| 2010 FY | -922.83 Million KRW | -114.79% |
| 2010 Q3 | -130.14 Million KRW | -102.26% |
| 2010 Q2 | 5.76 Billion KRW | -28.81% |
| 2009 FY | 6.23 Billion KRW | 699.01% |
| 2009 Q3 | 4.77 Billion KRW | 732.82% |
| 2009 Q2 | -755.01 Million KRW | 82.62% |
| 2009 Q1 | -4.34 Billion KRW | -656.47% |
| 2008 Q1 | -9.02 Billion KRW | 39.0% |
| 2008 Q2 | -3.53 Billion KRW | 60.78% |
| 2008 Q3 | -871.86 Million KRW | 75.36% |
| 2008 Q4 | 780.79 Million KRW | 189.55% |
| 2008 FY | 780.79 Million KRW | 105.28% |
| 2007 Q2 | -14.54 Billion KRW | 31.66% |
| 2007 FY | -14.79 Billion KRW | 0.0% |
| 2007 Q4 | -14.79 Billion KRW | -27.99% |
| 2007 Q3 | -11.55 Billion KRW | 20.53% |
| 2007 Q1 | -21.27 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | -3.06 Billion KRW | 362.24% |
| Green Cross Holdings Corporation | 1105.62 Billion KRW | 99.272% |
| Green Cross Holdings Corporation | 674.31 Billion KRW | 98.806% |
| Pharmicell Co., Ltd. | -10.69 Billion KRW | 175.248% |
| Green Cross Corporation | 674.31 Billion KRW | 98.806% |
| Celltrion, Inc. | 1325.8 Billion KRW | 99.393% |
| Samsung Biologics Co.,Ltd. | 1541.39 Billion KRW | 99.478% |
| SK bioscience Co.,Ltd. | -106.45 Billion KRW | 107.561% |
| SK Biopharmaceuticals Co., Ltd. | -61.64 Billion KRW | 113.056% |
| Prestige BioPharma Limited | -129.76 Billion KRW | 106.203% |